No abstract

No abstract

No abstract

There is a high rate of clinical and chemical freedom from progression following 125I implantation for select patients with early stage prostatic carcinoma.

William Cavanagh, B.S. 3 Posttherapy evaluation included clinical, biochemical (PSA), and pathologic (repeat needle biopsy) studies. No patient was surgically staged, and none received andro-1 Pacific Northwest Cancer Foundation/Northgen deprivation therapy. Morbidity was graded according to the Radiation Therapy west Hospital, Seattle, Washington.Oncology Group grading scale. Statistical appraisal was performed by the Kaplan-2 Department of Urology, University of WashMeier method. PSA failure was defined in two ways: (1) PSA progression, i.e., 2 ington, Seattle, Washington.consecutive increases from a nadir value; and (2) failure to attain an arbitrary serum PSA value of 1.0 or 0.5 ng/mL at last follow-up. 3 Department of Radiation Oncology, University RESULTS. The overall 7-year survival was 77%; there were no deaths from prostate of Washington, Seattle, Washington.carcinoma in this cohort. The 7-year actuarial PSA progression free outcome was 4 Northwest Tumor Institute, Seattle, Washing-89%, and the PSA°1.0 ng/mL outcome was 87%. When PSA°0.5 ng/mL was ton.selected as an outcome end point, and PSA values in this series of radiation-treated 5 Pathology Associates Inc., Spokane, Washingpatients were compared with PSA values proposed to indicate disease free survival ton.after radical prostatectomy (PSA°0.3-°0.6 ng/mL), the 7-year actuarial disease free survival was 79%. Morbidity was minimal except in patients who had preimplant or postimplant transurethral prostate resection. CONCLUSIONS.Outpatient-based iodine-125 prostate brachytherapy for prostate carcinoma classified as T1 or T2 resulted in biochemical outcomes comparable to end points resulting from radical prostatectomy and external beam radiation.